A Case of Anterior Vitreous Displacement of the Intravitreal Dexamethasone Implant (Ozurdex®) in a Pseudophakic Eye.

Macular edema following branch retinal vein occlusion (BRVO) is a common cause of visual impairment. Treatment options include intravitreal anti-vascular endothelial growth factor injections as first-line therapy, followed by a dexamethasone implant (Ozurdex®), preservative-free triamcinolone, and macular laser photocoagulation. Here, we present a case of anterior vitreous displacement of the Ozurdex® implant, a rare non-pharmacological complication. An 88-year-old pseudophakic woman with BRVO and macular edema received an intravitreal dexamethasone implant (Ozurdex®). After the injection, she reported a rod-like floater. Examination revealed no visual loss or raised intraocular pressure. The implant was located behind the intraocular lens in the anterior vitreous, with stable macular optical coherence tomography and fundus findings. Conservative follow-up was chosen, and the implant dissolved over four months without complications. This rare displacement contrasts with anterior chamber migration, which can be vision-threatening. Anterior vitreous displacement of an Ozurdex® implant in a pseudophakic eye is benign and does not require surgical intervention. A conservative "watch-and-wait" approach with close monitoring is sufficient. Our case emphasizes preventive strategies, including identifying at-risk patients, using a careful injection technique, and performing meticulous slit-lamp evaluation in cases of migration.